GSK was the first global healthcare company to establish a presence in Singapore in 1959.
For over 60 years, GSK has been an important contributor to the healthcare system and the biopharma manufacturing sector in Singapore. We are one of the biggest contributors to Singapore's biomedical sciences industry with investments of more than S$2.5 billion (£1.5 billion).
Singapore is the headquarters for our Global General Medicines (GM) business, and is also the regional headquarters for our Greater China and Intercontinental (GCI) and Emerging Markets (EM) regions. It houses 3 vital manufacturing sites, comprising two global manufacturing supply sites and a vaccines manufacturing facility.
We are proud to have helped create high value jobs across commercial and advanced manufacturing sectors in Singapore, developing local talent and capability through scholarships, apprenticeship/training programmes and leadership development programs. Today we employ over 1,500 people in Singapore, every one of whom share our mission to get ahead of disease together.
Our sites in Singapore
In Singapore, our business is spread across four sites – two global pharmaceutical manufacturing sites, a global vaccines manufacturing site and our corporate and commercial office.
Corporate and commercial offices
GSK Asia House is the regional headquarters of our Emerging Markets and Asia Pacific biopharmaceutical businesses. It is also the global headquarters of our General and Specialty Medicines groups, and home to our commercial operations for the Singapore market.
GSK Asia House
23 Rochester Park
Tel: +65 6232 8338
Our Jurong site opened in 1982. The site, which now sits on a nine-hectare site, has evolved from bulk manufacture of established products in the early days to becoming a leading new product introductions (NPI) site within our pharma supply chain, producing new innovative medicines in areas including HIV and oncology.
It is focused on the development of late phase new chemical entities (NCEs) and delivering higher value products such as very active compounds in small batch sizes. The site currently has an R&D Pilot Plant where NCEs are developed and scaled up, and three production buildings making 13 active pharmaceutical ingredients for a range of medicines prescribed for the treatment of respiratory, oncology, allergy, anti-viral and neurological conditions.
In 2014, the Jurong site built a commercial continuous processing plant using new hybrid continuous-batch synthesis, the first of its kind within our pharma supply chain. In 2019, the site opened new production facilities worth S$130m, including two continuous manufacturing facilities, and an expansion of one of the site’s production buildings.
Jurong global manufacturing site
1 Pioneer Sector 1
Quality Road is one of the world’s largest amoxicillin facilities and Singapore’s first pharmaceuticals manufacturing plant. Built in 1972 at a cost of over S$32 million, the site was officially opened in May 1973.
The site was originally built to produce a range of newly discovered semi-synthetic penicillin and had both primary and secondary production facilities to make the final dose forms. Over time, the site developed into one of GSK’s critical sites for the supply of Amoxicillin which is an active compound for the manufacture of our antibiotics.
In December 2021, GSK announced that it will cease manufacturing and outsource all production of amoxicillin that is currently produced at its Quality Road site in Singapore. This will result in the closure of the site, with manufacturing at the site expected to cease by the end of 2024.
Quality road global manufacturing site
38 Quality Road
With an investment of S$510 million, our state-of-the-art vaccines manufacturing facility at Tuas was opened in June 2009 by Singapore's Prime Minister Lee Hsien Loong, coinciding with our 50th anniversary in Singapore.
Comprising two production buildings, an administration block, quality control laboratories, utility plant and warehousing, the facility became operational in 2011. The facility and operations meet the high quality and good manufacturing standards of global regulatory bodies such as the European Medicines Agency.
Tuas is a key manufacturing site within our network supplying the active ingredient used to make our pneumococcal conjugate vaccine. This paediatric vaccine is indicated for the active immunisation against pneumonia caused by Streptococcus pneumoniae, invasive diseases and acute otitis media caused by Streptococcus pneumoniae in infants and children.
Tuas site also focuses on manufacturing Hib (Haemophilus influenzae type b) antigen which is used in the manufacture of several paediatric vaccines. Hib is a bacterium responsible for invasive diseases, such as severe pneumonia and meningitis, contracted almost exclusively by children less than five years old.
These two vaccine products manufactured at Tuas covers approximately 45% of the diseases causing paediatric mortality in the world, making a significant contribution to our global health agenda. The site continues to invest in developing technical capability and process improvement, and embracing new technology such as digital, data and analytics to position itself as the centre of excellence for the manufacture of vaccines.
Tuas global vaccines manufacturing facility
10 Tuas South Ave 8
GSK Asia House
23 Rochester Park
Tel: +65 6232 8338
The contact information provided here is specific to the purposes indicated. Any unrelated requests sent to these emails will not be attended to. For general enquiries, please contact our general enquiries telephone line +65 6232 8338.
Health professionals in Singapore can obtain information about products and areas of therapy related to GSK by visiting the GSKPro Singapore page.
GSK celebrates the groundbreaking ceremony of the facility expansion that will produce drug substances for GSK’s leading vaccines that prevent Hepatitis B.
GSK announced the opening of a S$44 million high potency facility (HPF) in its strategic New Product Introduction site in Jurong, Singapore. The opening of the facility was officiated by Guest-of-Honour, Singapore’s Minister for Health, Mr. Ong Ye Kung, and Mr. Regis Simard, GSK’s President, Global Supply Chain.
GSK announced that it will cease manufacturing and outsource all production of amoxicillin that is currently produced at its Quality Road site in Singapore. This will result in the closure of the site with manufacturing at the site expected to cease by the end of 2024.
GSK Singapore is contracted to supply the Government of Singapore with additional doses of Sotrovimab, following the first purchase placed by the Ministry of Health (MOH) in June 2021.
GSK Singapore and Vir Biotechnology announced an advance purchase agreement with the Government of Singapore for the supply of sotrovimab, an investigational single-dose monoclonal antibody, for the treatment of patients with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19.
GSK Singapore and Vir Announce APA with Singapore MOH (PDF 111.4KB)